{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:53:58Z","timestamp":1793832838760,"version":"4.6.1"},"reference-count":53,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Onychomycosis is the most common affliction of the nail. It may be caused by dermatophytes, yeasts, and non-dermatophyte molds. Traditionally, oral antifungal treatments have been used to treat the fungus, although they can be accompanied by side effects and drug interactions. Topical treatments provide an alternative modality, bypassing the systemic effects of oral drugs; recent research has centered on topical drug improvement and development. Physical and laser treatments are being used in conjunction with topicals, which may help penetrate the thick nail plate. In this review, techniques from all categories are outlined: both novel experimental approaches and progress and effectiveness of recently developed treatments. More long-term studies are required to determine the efficacy of various treatments, but cure rates are improved when patients adhere to treatments and follow preventative measures to avoid disease recurrence.<\/ns4:p>","DOI":"10.12688\/f1000research.18646.1","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T15:45:24Z","timestamp":1561477524000},"page":"968","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Recent advances in therapies for onychomycosis and its management"],"prefix":"10.12688","volume":"8","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"305-18","DOI":"10.1016\/j.cpm.2016.02.001","article-title":"Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes.","volume":"33","author":"T Vlahovic","year":"2016","journal-title":"Clin Podiatr Med Surg."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"853-67","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: Treatment and prevention of recurrence.","volume":"80","author":"S Lipner","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"151-9","DOI":"10.1016\/j.clindermatol.2009.12.006","article-title":"Onychomycosis.","volume":"28","author":"O Welsh","year":"2010","journal-title":"Clin Dermatol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"123-33","DOI":"10.1007\/s40257-018-0403-4","article-title":"A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level.","volume":"20","author":"A Gupta","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"211-6","DOI":"10.3390\/jof1020211","article-title":"Environmental and Genetic Factors on the Development of Onychomycosis.","volume":"1","author":"C Adams","year":"2015","journal-title":"J Fungi (Basel)."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"415-29","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management.","volume":"11","author":"B Elewski","year":"1998","journal-title":"Clin Microbiol Rev."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"17-9","DOI":"10.1111\/j.1468-3083.2005.01283.x","article-title":"Genetic predisposition--understanding underlying mechanisms of onychomycosis.","volume":"19 Suppl 1","author":"J Faergemann","year":"2005","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"665-71","DOI":"10.1046\/j.1365-2133.1998.02464.x","article-title":"Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey.","volume":"139","author":"A Gupta","year":"1998","journal-title":"Br J Dermatol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"466-9","DOI":"10.1046\/j.1468-3083.2000.00124.x","article-title":"The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease.","volume":"14","author":"A Gupta","year":"2000","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"746-53","DOI":"10.1046\/j.1365-4362.2000.00012.x","article-title":"Epidemiology and prevalence of onychomycosis in HIV-positive individuals.","volume":"39","author":"A Gupta","year":"2000","journal-title":"Int J Dermatol."},{"key":"ref-11","first-page":"363-385","article-title":"Structural characteristics and permeability properties of the human nail: A review.","volume":"50","author":"G Gupchup","year":"1999","journal-title":"J Cosmet Sci."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"227-36","DOI":"10.1517\/14656566.2015.993380","article-title":"New pharmacotherapy for the treatment of onychomycosis: an update.","volume":"16","author":"A Gupta","year":"2015","journal-title":"Expert Opin Pharmacother."},{"key":"ref-13","doi-asserted-by":"crossref","DOI":"10.1002\/9781119323396","article-title":"Baran & Dawber\u2019s diseases of the nails and their management","author":"R Baran","year":"2019"},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"461-475","DOI":"10.1093\/mmy\/myw084","article-title":"Chemical and physical strategies in onychomycosis topical treatment: A review.","volume":"55","author":"T Angelo","year":"2017","journal-title":"Med Mycol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"2-4","DOI":"10.3109\/09546634.2015.1034081","article-title":"Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis.","volume":"27","author":"A Gupta","year":"2016","journal-title":"J Dermatolog Treat."},{"key":"ref-16","article-title":"Kerydin (tavaborole) topical solution, 5%","author":"I Anacor Pharmaceuticals","year":"2014"},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1759-61","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.","volume":"316","author":"F Rock","year":"2007","journal-title":"Science."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"62-9","DOI":"10.1016\/j.jaad.2015.04.010","article-title":"Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.","volume":"73","author":"B Elewski","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"44-8","DOI":"10.1080\/09546634.2017.1329510","article-title":"Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies.","volume":"29","author":"A Gupta","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"ref-20","article-title":"Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w\/w (10 mg\/g) topical spray solution 1% w\/w (10 mg\/g) Antifungal Agent","year":"2013"},{"key":"ref-21","article-title":"SPORANOX\u00ae (itraconazole) Capsules","year":"2017"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"600-8","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.","volume":"68","author":"B Elewski","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"ref-23","article-title":"PrJUBLIATM Efinaconazole Topical Solution, 10% w\/w","author":"L Valeant Canada","year":"2013"},{"key":"ref-24","article-title":"PENLAC\u00ae Nail Lacquer (ciclopirox) Topical Solution, 8%"},{"key":"ref-25","article-title":"LUZU (luliconazole) Cream, 1% for topical use","author":"I Valeant Pharmaceuticals","year":"2013"},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"3553-5","DOI":"10.1128\/AAC.02706-13","article-title":"Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.","volume":"58","author":"N Wiederhold","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"753-9","DOI":"10.1111\/1346-8138.13816","article-title":"Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.","volume":"44","author":"S Watanabe","year":"2017","journal-title":"J Dermatol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"773-81","DOI":"10.1111\/j.1468-3083.2009.03164.x","article-title":"An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.","volume":"23","author":"R Baran","year":"2009","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"134-40","DOI":"10.1159\/000441569","article-title":"Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator.","volume":"1","author":"M Iorizzo","year":"2016","journal-title":"Skin Appendage Disord."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"13-9","DOI":"10.1159\/000488606","article-title":"Ciclopirox Hydroxypropyl Chitosan: Efficacy in Mild-to-Moderate Onychomycosis.","volume":"5","author":"B Piraccini","year":"2018","journal-title":"Skin Appendage Disord."},{"key":"ref-31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040276","article-title":"Polyurethanes as New Excipients in Nail Therapeutics.","volume":"10","author":"B Valdes","year":"2018","journal-title":"Pharmaceutics."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"873-80","DOI":"10.1128\/AAC.01790-15","article-title":"Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis.","volume":"60","author":"S Takahata","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"ref-33","article-title":"Efficacy and Safety Study of ME1111 in Patients With Onychomycosis","year":"2013"},{"key":"ref-34","article-title":"Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis","year":"2012"},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"E93-E110","DOI":"10.3314\/mmj.16-00006","article-title":"Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.","volume":"57","author":"H Yamaguchi","year":"2016","journal-title":"Med Mycol J."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1151-9","DOI":"10.1111\/1346-8138.14607","article-title":"Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.","volume":"45","author":"S Watanabe","year":"2018","journal-title":"J Dermatol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"3455-8","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors.","volume":"24","author":"W Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett."},{"key":"ref-38","article-title":"Efficacy and Safety of VT-1161 in a Randomized, Double-Blind, Placebo-Controlled Study of Four Oral VT-1161 Regimens in the Treatment of Patients with Moderate-to-Severe Distal-Lateral Subungual Onychomycosis (DLSO)","author":"B Elewski","year":"2017"},{"key":"ref-39","article-title":"A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail","year":"2017"},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1097-106","DOI":"10.2217\/fmb.13.86","article-title":"Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment.","volume":"8","author":"J Heinlin","year":"2013","journal-title":"Future Microbiol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"295-8","DOI":"10.1111\/ced.12973","article-title":"Pilot study to evaluate a plasma device for the treatment of onychomycosis.","volume":"42","author":"S Lipner","year":"2017","journal-title":"Clin Exp Dermatol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"72-7","DOI":"10.1016\/j.jconrel.2017.10.014","article-title":"Precise laser poration to control drug delivery into and through human nail.","volume":"268","author":"S Vanstone","year":"2017","journal-title":"J Control Release."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"237-44","DOI":"10.1016\/j.ijpharm.2017.11.008","article-title":"Enhancement of tioconazole ungual delivery: Combining nanocapsule formulation and nail poration approaches.","volume":"535","author":"F Flores","year":"2018","journal-title":"Int J Pharm."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"56-63","DOI":"10.1016\/j.ejps.2016.12.043","article-title":"An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment.","volume":"100","author":"F Flores","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"ref-45","doi-asserted-by":"crossref","first-page":"114-6","DOI":"10.1177\/1203475416677722","article-title":"Lasers for Onychomycosis.","volume":"21","author":"A Gupta","year":"2017","journal-title":"J Cutan Med Surg."},{"key":"ref-46","doi-asserted-by":"publisher","DOI":"10.3390\/jof4030099","article-title":"Therapy of Skin, Hair and Nail Fungal Infections.","volume":"4","author":"R Hay","year":"2018","journal-title":"J Fungi (Basel)."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"33-8","DOI":"10.1111\/ddg.12251_suppl","article-title":"Lasertherapie der Onychomykose.","volume":"12","author":"P Nenoff","year":"2014","journal-title":"J Dtsch Dermatol Ges."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1253-8","DOI":"10.3109\/03639045.2011.568946","article-title":"Transungual delivery of terbinafine by iontophoresis in onychomycotic nails.","volume":"37","author":"A Nair","year":"2011","journal-title":"Drug Dev Ind Pharm."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"e18158","DOI":"10.5812\/jjm.18158v2","article-title":"The Efficacy of Ultraviolet Irradiation on Trichophyton Species Isolated From Nails.","volume":"8","author":"A Nematollahi","year":"2015","journal-title":"Jundishapur J Microbiol."},{"key":"ref-50","article-title":"510(k) Summary K093547","author":"U Pinpointe","year":"2010"},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"301-7","DOI":"10.2310\/7750.2012.12060","article-title":"Laser therapy for onychomycosis.","volume":"17","author":"A Gupta","year":"2013","journal-title":"J Cutan Med Surg."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1757-1146-7-34","article-title":"The effectiveness of lasers in the treatment of onychomycosis: a systematic review.","volume":"7","author":"I Bristow","year":"2014","journal-title":"J Foot Ankle Res."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"83-7","DOI":"10.1159\/000448056","article-title":"Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence.","volume":"2","author":"A Tosti","year":"2016","journal-title":"Skin Appendage Disord."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-968\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-968\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-968\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T09:30:08Z","timestamp":1561541408000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-968\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":53,"URL":"https:\/\/doi.org\/10.12688\/f1000research.18646.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.20413.r50100","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.20413.r50099","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-968\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.20413.r50100, Chris G. Adigun, Dermatology & Laser Center of Chapel Hill, Chapel Hill, NC, USA, 26 Jun 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-968\/v1#referee-response-50100","order":0,"name":"referee-response-50100","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.20413.r50099, Evan Rieder, The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA, 26 Jun 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-968\/v1#referee-response-50099","order":1,"name":"referee-response-50099","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}